Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created
following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30
years, Alexion is focused on serving patients and families affected by rare diseases and devastating
conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves
patients in more than 50 countries.
